Skip to main
ACHL
ACHL logo

ACHL Stock Forecast & Price Target

ACHL Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 20%
Buy 20%
Hold 20%
Sell 40%
Strong Sell 0%

Bulls say

Achilles Therapeutics PLC has made significant strides in manufacturing enhancements for its precision T-cell therapies, notably achieving a median cNeT dose of 611 million cells in its most recent production cycle, indicating a substantial advancement in its capabilities. The company has also reported that the time required for harvesting, activation, and expansion of cNeTs is improving, with a target lead time now set at 6-8 weeks, further optimizing the production process. Additionally, translational analyses suggest that the company's enhanced conditioning regimens are resulting in improved persistence of cNeTs in patients, supporting a positive outlook for their ongoing clinical trials and overall therapeutic potential.

Bears say

Achilles Therapeutics PLC faces significant risks that contribute to a negative outlook on its stock, primarily due to potential rare or unexpected side effects from its therapies, which could necessitate downward revisions of projections and valuations. The uncertainty surrounding regulatory approvals poses another major concern, as achieving clinical trial endpoints does not guarantee clearance from regulatory bodies, thereby impacting risk-adjusted projections. Additionally, delays in development timelines, possibly related to alignment issues with regulatory agencies on product release criteria, could undermine investor confidence and further affect the company's financial projections.

ACHL has been analyzed by 5 analysts, with a consensus rating of Hold. 20% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 40% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Achilles Therapeutics PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Achilles Therapeutics PLC (ACHL) Forecast

Analysts have given ACHL a Hold based on their latest research and market trends.

According to 5 analysts, ACHL has a Hold consensus rating as of Jul 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Achilles Therapeutics PLC (ACHL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.